netFormulary NHS
Sunderland Joint Formulary
NHS Sunderland Clinical Commissioning Group
South Tyneside and Sunderland NHS Foundation Trust
 Search
 Formulary Chapter 8: Malignant disease and immunosuppression - Full Chapter
Chapter Links...
 Details...
08.01  Expand sub section  Cytotoxic drugs
08.01  Expand sub section  Side-effects of cytotoxic drugs
08.01  Expand sub section  Drugs for cytotoxic-induced side-effects
Calcium Folinate (Folinic acid)
View adult BNF View SPC online
Formulary
Red

Tablets: 15mg
Injection: 3mg, 15mg, 30mg and 300mg
An unlicensed 1mg per 1ml mouthwash can be prepared if needed unlicensedunlicensed 

 
   
Dexrazoxane (Savene)
View adult BNF View SPC online
Formulary
Red
High Cost Medicine

Vials: 500mg (with diluent)
- for use in line with NECN extravasation

 
   
Glucarpidase
View adult BNF View SPC online
Formulary
Red

unlicensedunlicensed Vials: 1000units -approved for the urgent treatment of methotrexate-induced renal dysfunction (subject to NHS England funding)

 
   
Mesna
View adult BNF View SPC online
Formulary
Red

Injection: 1g in 10ml
Tablets: 400mg

 
   
Pegasparagase
View adult BNF View SPC online
Formulary
Red

Vial: 3750 international units

 
Link  NICE TA 408: Pegaspargase for treating acute lymphoblastic leukaemia
   
08.01.01  Expand sub section  Alkylating drugs
08.01.02  Expand sub section  Anthracyclines and other cytotoxic antibiotics to top
08.01.03  Expand sub section  Antimetabolites
08.01.04  Expand sub section  Vinca alkaloids and etoposide
08.01.05  Expand sub section  Other antineoplastic drugs
08.01.05  Expand sub section  Amsacrine
08.01.05  Expand sub section  Arsenic trioxide to top
08.01.05  Expand sub section  Bevacizumab
08.01.05  Expand sub section  Bexarotene
08.01.05  Expand sub section  Bortezomib
08.01.05  Expand sub section  Brentuximab vedotin
08.01.05  Expand sub section  Cetuximab to top
08.01.05  Expand sub section  Crisantaspase
08.01.05  Expand sub section  Dacarbazine and Temozolomide
08.01.05  Expand sub section  Erlotinib
08.01.05  Expand sub section  Hydroxycarbamide
08.01.05  Expand sub section  Imatinab to top
08.01.05  Expand sub section  Ipilimumab
08.01.05  Expand sub section  Mitotane
08.01.05  Expand sub section  Panitumumab
08.01.05  Expand sub section  Pentostatin
08.01.05  Expand sub section  Platinum compounds to top
08.01.05  Expand sub section  Porfimer sodium and temoporfin
08.01.05  Expand sub section  Procarbazine
08.01.05  Expand sub section  Protein kinase inhibitors
08.01.05  Expand sub section  Taxanes
08.01.05  Expand sub section  Topoisomerase I inhibitors to top
08.01.05  Expand sub section  Trabectedin
08.01.05  Expand sub section  Trastuzumab
08.01.05  Expand sub section  Tretinoin
08.01.05  Expand sub section  Vismodegib
 ....
 Non Formulary Items
Calcium Leofolinate  (Isovorin®)

View adult BNF View SPC online
Non Formulary
 
Disodium Folinate  (Sodiofolin®)

View adult BNF View SPC online
Non Formulary
 
Disodium Levofolinate

View adult BNF View SPC online
Non Formulary
 
Palifermin  (Kepivance)

View adult BNF View SPC online
Non Formulary
 
  
Key
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Unlicensed
Track Changes
Display tracking information
click to search medicines.org.uk
Link to adult BNF
click to search medicines.org.uk
Link to SPCs
Cytotoxic Drug
Cytotoxic Drug
CD
Controlled Drug
High Cost Medicine
High Cost Medicine
Cancer Drugs Fund
Cancer Drugs Fund
NHSE
NHS England
Homecare
Homecare
CCG
CCG

Traffic Light Status Information

Status Description

Red

Drugs for hospital use or use by a specialist within specialist centre only. Initiation and monitoring of treatment should remain under the total responsibility of the appropriate hospital clinician or specialist. These drugs should only be prescribed under the direct supervision of that clinician or specialist and are not suitable for shared care arrangements. The drug should be supplied via the hospital or specialist centre for the duration of treatment.   

Amber

These are specialist drugs which must be initiated by secondary care specialist prescribers, but with the potential to transfer prescribing to primary care within written and agreed shared care protocols and according to the agreed process for transfer of care. For these drugs, in order to ensure patient safety, some aspects of care must remain with the specialist due to their complexity e.g. monitoring of disease or drug response. Other more routine aspects can be transferred to the GP e.g. monitoring of adverse effects and supply of the medicine. The specific responsibilities of the specialist and GP are defined in the shared care agreement for each drug. Shared care agreements are still under development for some amber drugs. Until these are available, it would be expected that any shared care request from secondary care to a GP would be accompanied by written information which defines prescribing and monitoring responsibilities. The hospital specialist should also provide the GP with enough information and support to allow the safe transfer and ongoing management of prescribing into primary care.   

Green +

Drugs which should usually be initiated in secondary care, or by a specialist clinician, but can be safely maintained in primary care with very little or no monitoring required. In some cases there may be a further restriction for use outlined - these will be defined in each case.  

Green

These are defined as new and established drugs, which may be prescribed, initiated, changed or maintained on FP10 by the GP and, if appropriate, discontinued without recourse to secondary care. N.B. DRUGS NOT IDENTIFIED IN THE FORMULARY BY A RED, AMBER OR GREEN+ SYMBOL ARE CLASSIFIED AS GREEN.   

netFormulary